News

Cellectis Showcases Innovations in Non-Viral Gene Therapy at Congress

Cellectis Showcases Innovations in Non-Viral Gene Therapy at Congress

Exciting Advances in Gene Therapy by Cellectis

Cellectis, a clinical-stage biotechnology company, is making headlines with its innovative approach to gene therapy, particularly in the exciting world of gene editing. Recently, the company announced significant findings regarding the potential of circular single-stranded DNA (CssDNA) as a universal non-viral template for gene therapies. These findings will be presented at the European Society of Cell and Gene Therapy (ESGCT) annual congress.

Details of the Presentation

One of the highlights of Cellectis' presentation is the poster titled "Circularization of Single-Stranded DNA Donor Template Unleashes the Power of Non-Viral Gene Delivery for Long-Term HSCs editing," to be presented by Julien Valton, Ph.D., Vice President of Gene Therapy.

Key Aspects of the Research

This innovative research emphasizes the use of CssDNA for gene editing, showcasing its effectiveness in hematopoietic stem and progenitor cells (HSPCs). Over the last decade, the non-viral DNA template has been utilized with engineered nucleases, but Cellectis has taken this a step further by expanding its application.

Research Findings and Efficacy

The results from the research are compelling:

  • CssDNA shows a high gene insertion frequency within viable HSPCs.
  • In murine models, CssDNA-edited HSPCs demonstrate superior engraftment and retention of gene edits compared to those edited using adeno-associated viruses (AAV).

These findings underline the promise of CssDNA as an effective tool in the realm of gene therapy, poised to transform therapeutic approaches.

Exploring TALE Base Editors

Another significant aspect of Cellectis' work involves TALE base editors (TALEB). These editors play a crucial role in genome editing without necessitating a DNA break. Maria Feola, Ph.D., Senior Scientist at Cellectis, will present on the "Comprehensive analysis of TALEB off-target editing."

Understanding TALEB Mechanism

The TALEB technology combines several advanced elements, including a transcription activator-like effector and a deaminase, providing a refined method for editing double-stranded DNA. Key to its success is the ability to minimize off-target effects, which remains paramount in developing safe therapeutic applications.

Evaluating Safety and Effectiveness

In assessing the safety of TALEB, Cellectis employed advanced bioinformatics alongside multiple experimental approaches. The study showed no inclination toward off-target C-to-T editing at critical sites, laying a robust foundation for future development and application in therapeutic cell engineering.

About Cellectis

Cellectis is recognized for its pioneering efforts in the biotechnology sector, utilizing an allogeneic strategy for CAR T immunotherapies in oncology. By focusing on ready-to-use gene-edited CAR T-cells, Cellectis aims to provide effective treatments for cancer patients, broadening its research into other therapeutic avenues as well. The company’s commitment to an end-to-end approach in gene editing demonstrates its dedication to control across the entire value chain of cell and gene therapy.

Company Contacts and Further Information

Cellectis maintains its headquarters in Paris, France, with additional locations in New York and Raleigh, NC. As a publicly traded company, it operates on Nasdaq under the ticker symbol CLLS. For more about their innovative research and developments, it is advisable to visit their official website or connect via their social media platforms.

Frequently Asked Questions

What is Cellectis' main area of research?

Cellectis focuses on gene editing and gene therapy applications, particularly in the treatment of cancer through CAR T-cell therapies.

Where will the ESGCT Congress take place?

The congress will host multiple presentations highlighting new research and advancements, taking place in Sevilla.

What are TALE base editors?

TALE base editors are specialized tools utilized for precise genome editing, enabling direct conversion of DNA bases without creating breaks in the DNA strands.

What are the advantages of using CssDNA in gene therapy?

CssDNA provides a versatile and efficient non-viral delivery method for gene editing applications, showing promising results in HSPC editing.

How can I learn more about Cellectis' research?

Further details can be found on Cellectis' official website, where they share research publications and company news.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 102

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 124

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 76

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 63

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 72

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading

Top 5 Most Recently Viewed Articles

Seasonal Hiring Booms as Firms Eye Long-Term Talent

Updated Category News Views 327

A Strategic Shift in Seasonal Hiring It ain't just about the holiday rush anymore, folks. Companies are waking up to the idea that seasonal gigs are more than a temporary Band-Aid. This year, nearly 2 out of 5 companies are planning to bring more seasonal folks into the fold compared to last year. That means a good dose of them are looking for longer-term value—like...

Continue Reading
Nebius Secures $700 Million to Accelerate AI Infrastructure Growth

Updated Category News Views 269

Nebius Secures $700 Million to Accelerate AI Infrastructure Growth Nebius Group N.V. (“Nebius Group”, “Nebius” or the “Company”; NASDAQ:NBIS), a prominent player in AI infrastructure, has made an exciting announcement regarding a substantial private placement financing. In a strategic move to bolster its operations, the company has secured USD 700 million from...

Continue Reading
Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO

Updated Category News Views 183

Xenon Pharmaceuticals Welcomes Tucker Kelly as CFO Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a biopharmaceutical company specializing in neuroscience, has made a significant move by appointing Tucker Kelly as the new Chief Financial Officer (CFO). This decision signals the company's commitment to strategic financial management as it gears up for the commercialization of...

Continue Reading
Brookfield Makes Big Moves in Japan's Real Estate Market

Updated Category News Views 302

Brookfield's Bold Ventures into Japan's Real Estate Landscape Canadian investment firm Brookfield Asset Management (TSX: BAM) has recently made headlines with its significant real estate endeavors in Japan, closing two major deals that amount to a staggering $1.6 billion. The Significant Investments Overview The recent acquisitions involve a noteworthy stake in the iconic...

Continue Reading
Pacira BioSciences Facing Legal Challenges and Investor Updates

Updated Category News Views 170

Legal Proceedings Impacting Pacira BioSciences, Inc. Shareholders of Pacira BioSciences, Inc. should be aware of a significant class action lawsuit that is currently unfolding. This lawsuit, noted for its complexity, aims to address allegations of securities fraud impacting investors. The firm representing the investors, is Levi & Korsinsky, a well-established legal group...

Continue Reading